Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Zinc Finger Protein Transcription Factor-Mediated Repression of Alpha-Synuclein Expression as a Therapeutic Approach for Parkinson’s Disease

Download PDF